An Open-Label Non-Randomized Multi-Center Phase-2 Study of

An Open-Label Non-Randomized Multi-Center Phase-2 Study of
99 years or below
All
Phase 2
1 Location

Brief description of study

An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Recurrent or Progressive Glioblastoma. The main purpose of the study is to determine the objective response rate (ORR) per a modified RANO criteria following intra- and peritumoral infusion using convection-enhanced delivery (CED) of MDNA55 relative to pre-operative planning MRI (baseline).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD, tbd, tbd
  • Age: 99 years or below
  • Gender: All
Updated on 27 Aug 2018. Study ID: 828586

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.